10 years of historical data (2015–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Cibus, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $106M | $65M | $203M | $4.3B | $61.6B | $143.0B | $230.0B | $317.9B | $510.1B | — | — |
| Enterprise Value | $128M | $86M | $194M | $4.3B | $61.6B | $143.0B | $229.9B | $317.8B | $510.0B | — | — |
| P/E Ratio → | -0.33 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 24.84 | 15.15 | 111.49 | 27265.46 | 2370.69 | 5994.87 | 31519.68 | 1346949.25 | 1004084.47 | — | — |
| P/B Ratio | 0.85 | 0.66 | 0.60 | 591.81 | 4359.39 | 3877.54 | 3679.02 | 3403.53 | 8874.55 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 20.27 | 107.04 | 27332.24 | 2370.84 | 5994.98 | 31514.20 | 1346630.15 | 1003992.90 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Cibus, Inc. earns an operating margin of -6062.8%. Operating margins have expanded from -14248.4% to -6062.8% over the past 3 years, signaling improving operational efficiency. A negative ROE of -115.3% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 78.3% | -877.1% | -9.9% | -47.3% | -27.2% | -358.1% | -8.5% | 49.9% | 41.0% |
| Operating Margin | -6062.8% | -6062.8% | -17550.0% | -14248.4% | -112.9% | -183.8% | -543.8% | -11913.1% | -5076.6% | -3034.8% | -457.1% |
| Net Profit Margin | -5898.4% | -5898.4% | -14729.1% | -10758.6% | -112.4% | -188.0% | -542.9% | -11820.8% | -5114.2% | -3029.1% | -463.0% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -115.3% | -115.3% | -154.9% | -158.1% | -114.5% | -90.2% | -50.8% | -37.0% | -73.6% | -64.7% | -24.3% |
| ROA | -56.2% | -56.2% | -94.4% | -56.7% | -58.1% | -59.2% | -38.3% | -29.2% | -58.5% | -56.7% | -22.7% |
| ROIC | -86.2% | -86.2% | -137.5% | -93.5% | -76.5% | -106.3% | -146.6% | -145.2% | -203.0% | -237.0% | — |
| ROCE | -60.6% | -60.6% | -117.3% | -84.3% | -66.1% | -63.9% | -41.2% | -31.3% | -63.2% | -62.6% | -23.3% |
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $22M ($36M total debt minus $14M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.37 | 0.37 | 0.07 | 1.92 | 1.26 | 0.54 | 0.30 | 0.20 | 0.18 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.22 | -0.02 | 1.45 | 0.29 | 0.07 | -0.64 | -0.81 | -0.81 | -0.38 | -1.02 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -7.56 | -7.56 | -16.88 | -257.13 | -20.50 | -30.54 | -26.63 | -22.37 | -25789.00 | -2421.80 | -22.28 |
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.85x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 2.49x to 0.85x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.85 | 0.85 | 1.65 | 2.49 | 3.13 | 5.70 | 8.83 | 13.64 | 13.51 | 1.91 | 24.16 |
| Quick Ratio | 0.85 | 0.85 | 1.65 | 2.49 | 3.13 | 5.50 | 8.47 | 13.45 | 13.51 | 1.91 | 24.16 |
| Cash Ratio | 0.73 | 0.73 | 1.53 | 2.06 | 2.85 | 4.18 | 8.14 | 13.39 | 13.32 | 1.75 | 23.83 |
| Asset Turnover | — | 0.01 | 0.00 | 0.01 | 0.70 | 0.38 | 0.08 | 0.00 | 0.01 | 0.02 | 0.05 |
| Inventory Turnover | 25.40 | — | — | — | — | 25.40 | 3.58 | 0.82 | — | — | — |
| Days Sales Outstanding | — | 89.15 | 106.47 | — | — | 74.79 | 56.13 | 71.14 | 119.99 | 143.62 | 95.84 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Cibus, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $23M | $10M | $578M | $578M | $678M | $656M | $614M | $463M | $532M | $532M |
Compare CBUS with 7 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| $106M | -0.3 | — | — | 100.0% | -6062.8% | -115.3% | -86.2% | — | |
| $7B | 26.6 | 9.9 | 2.8 | — | 65.6% | 7.7% | 6.7% | 5.7 | |
| $4B | -918.6 | 309.3 | 51.3 | 93.4% | -13.5% | -0.5% | -2.3% | 0.6 | |
| $2B | 6.7 | 5.4 | 8.5 | 72.3% | 38.5% | 29.1% | 16.8% | — | |
| $765M | 38.6 | 21.4 | 2.8 | 100.0% | 87.7% | 1.9% | 1.4% | — | |
| $321M | -15.8 | — | — | 99.3% | -140.3% | -16.2% | -37.6% | — | |
| $305M | -15.5 | — | — | 99.3% | -140.3% | -16.2% | -37.6% | — | |
| $30M | -0.0 | — | — | — | — | — | — | — | |
| Healthcare Median | — | 23.3 | 13.6 | 18.1 | 66.0% | -6.6% | -36.9% | -13.6% | 3.0 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 10 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CBUS stacks up against sector leader Royalty Pharma plc.
Start ComparisonCibus, Inc.'s current P/E ratio is -0.3x. This places it at the 50th percentile of its historical range.
Cibus, Inc.'s return on equity (ROE) is -115.3%. The historical average is -88.3%.
Based on historical data, Cibus, Inc. is trading at a P/E of -0.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Cibus, Inc. has 100.0% gross margin and -6062.8% operating margin.